The remaining genes (IL-1α, CXCL7, IL-18RAP, CCL3) have not been well-studied in glioma, with the exception of CCL3, which is shown to improve the response to dendritic cell vaccines of patients with GBM (107). This evidence concerns the gene CCL3 and central nervous system cancer.